Brief: Briacell Therapeutics Corp - Bria-Imt Receives FDA Fast Track Designation For Phase 3 Study
20/05/2025 12:31
May 20 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL THERAPEUTICS CORP - BRIA-IMT RECEIVES FDA FAST TRACK DESIGNATION FOR PHASE 3 STUDY Source text: ID:nGNX7B5RSk Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study